Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
We can see a decrease in the price for Hikma Pharmaceuticals. Compared to yesterday it has lost -€0.200 (-1.100%).
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | -1.100% | 2.825% | 4.598% | -24.793% | 3.409% | -5.208% | -36.806% |
| Indivior plc | -2.050% | -2.013% | -1.351% | 153.913% | -2.667% | 36.258% | 406.944% |
| Viatris Inc. | 5.980% | 3.081% | 9.539% | -4.480% | 3.227% | 1.257% | -27.500% |
| Repligen Corp. | 1.560% | -0.069% | 4.828% | -2.695% | 2.520% | -11.854% | -14.607% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat